** Shares of gene therapy maker Sarepta Therapeutics SRPT.O rise 1.8% to $51.19
** Wells Fargo starts coverage on SRPT with "overweight" rating and sets PT at $115
** The new price target represents more than double the upside to stock's last close
** Brokerage says SRPT's muscle disorder therapy, Elevidys, remains best option for most young patients with Duchenne muscular dystrophy, so commercial opportunity is largely intact
** SRPT said last week it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment
** Wells Fargo sees no significant impact to the company due to the event
** Brokerage expects global sales of $1.6 billion in 2025 and peak sales of $3.5 billion in 2028 for Elevidys
** Twenty of 24 brokerages rate the stock "buy" or higher, four "hold"; their median PT is $158.09 - data compiled by LSEG
** Up to last close, shares have fallen 58.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.